




Arvind K Bansal, Ph.D. is currently Professor and Head, department of Pharmaceutics at the National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar, Punjab, India. Dr. Bansal is leading a group of about 15 post-graduate and doctorate students, in various areas of Pharmaceutics like pre-formulation profiling, solid state characterization, improvement of aqueous solubility, enhancement of oral bioavailability and compaction physics. Dr. Bansal holds a masters (1988) and doctorate degree (1993) in Pharmacy from the University of Delhi. Dr. Bansal served in the pharmaceutical industry as a research scientist in major Indian pharmaceutical companies – JK Pharmaceuticals (now called Regent Drugs after being acquired by Teva Pharmaceuticals, Israel) and Ranbaxy Laboratories Limited.

At JK Pharmaceuticals Dr. Bansal conceptualised, evolved formulation strategies, developed and transferred the technology to production shop floor of products belonging to dry powder injection, suspension for reconstitution, immediate release and delayed release tablets, oral liquid suspension and capsules.

At Ranbaxy Labs limited, in addition to these activities Dr. Bansal was actively engaged in business, regulatory and legislative decision making process for timely launch of generics products in the domestic and international market. He also conceptualised and established a pharmaceutical research group focussing on pre-formulation and formulation development of New Chemical Entities (NCEs) leading to filing of two INDs. The activities of his group included characterization of physico-chemical (solid state pharmaceutics, aqueous solubility, pH solubility profiling, pH stability profiling, solid state stability, compatibility studies) and physico-technical (flow properties, hygroscopicity, and compaction studies) properties of the NCE, early formulation development, process development, fabrication of clinical trials batches and support to chemical and biology groups.

At NIPER (2000 till date) Dr. Bansal has developed expertise in characterization and stabilization of the amorphous form, polymorphism, pseudo-polymorphism, particle engineering, screening of salt forms and improvement of oral bioavailability. His group works with the mission statement - **‘developing science based industrially viable pharmaceutical technologies’** and works closely with pharmaceutical

industry to create opportunities for commercial exploitation of the products. His group has successfully executed more than 300 sponsored projects from Indian and overseas pharmaceutical companies, in the area of pre-formulation and formulation development. Dr. Bansal's lab has developed following platform technologies to improve delivery of 'difficult-to-deliver' drug molecules in the areas of amorphous solid dispersions, barrier coated amorphous particles, nano crystalline solid dispersions and SNEDDS.



Research Philosophy

He is engaged in teaching of post-graduate classes of Solid State Pharmaceutics, Product Development, Pharmaceutical Production Technology, Formulation Industry and Scale up Techniques, and a Ph.D. level course on Technological Aspects of Oral Modified Release Dosage Forms.

AWARDS AND HONORS

Appointed as Editorial Board Member of "Pharmaceutics", a journal published by MDPI (Multidisciplinary Digital Publishing Institute), Basel, Switzerland.

Appointed as Editorial Board Member of "Journal of Excipients and Food Chemicals", an open access journal published from USA, with affiliation to International Pharmaceutical Excipients Council (IPEC).

Appointed as Editorial Board Member of "Recent Patents on Drug Delivery & Formulation", a Journal published by Bentham Science Publishers Ltd.

AAiPS Distinguished Educator and Researcher Award for the Year 2008:

This award is given to a faculty member from a recognized Indian Pharmacy education and research center. This award offers a grant, funded by AAiPS, that covers participation at the AAPS Annual Meeting, usually held in North America. The mission of American Association of Indian Pharmaceutical Scientists (AAiPS) is to provide a forum for discussion, continuing education, and exchange of ideas on advances in pharmaceutical sciences and technology. It has a membership of over 700 comprising of pharmaceutical scientists, engineers and suppliers.

Appointed as Editorial Board Member of International Journal of Biosciences and Technology

Innocentive Award, in the area of formulation development for 3 consecutive years (April 2005, May 2006, May 2007):

Innocentive (www.innocentive.com) is a web-based community, managed by a sister concern of Eli Lilly,USA and facilitates pharmaceutical scientists to address challenges faced by chemical and pharmaceutical companies, from around the globe.

OPPI (Organisation of Pharmaceutical Producers of India (OPPI) Scientist Award 2006:

This award was conferred in September 2006, for outstanding contribution in the area of Pharmaceutics. The OPPI, established in 1965, is a premier organisation of pharmaceutical manufacturers in India. Its membership consists of companies with international collaboration and large Indian companies. It represents primarily research based companies in India. OPPI is not only an industry association but also a scientific and professional body.

SCIENTIFIC PUBLICATIONS

Patents

Granted

1. Bansal AK, Puri V, Chawla HPS, Kaul CL. ***Prolonged release injectable preparation of ketorolac.*** Indian Patent Application granted on 04.06.2009, No. **234519**.
2. Bansal AK, Gupta P, Kakumanu V. ***A process for the preparation of celecoxib composition with improved aqueous solubility.*** Indian Patent No.: **243294**; Patent filing date: **18.11.2002**; Patent grant date: **04/10/2010**
3. Bansal AK, Verma S. ***A process for coating highly water-soluble drugs,*** Indian Patent No.: **243918**; Patent filing date: **03.12.2002**; Patent grant date: **11.11.2010**

Applied

1. Bansal AK and Puri V. ***Fast dispersing multi layered stabilized amorphous particle and process thereof,*** provisional Indian Patent Application No. 1735/DEL/2010, filed on July 23, 2010
2. Bansal AK, Puri V and Kohli G. ***Quick disintegrating taste masked composition.*** International PCT Application No. PCT/IB2009/007032
3. Bansal AK, Munjal B, Patel S. ***Self-Nano-Emulsifying curcuminoids composition with Enhanced Bioavailability.*** International PCT Application No. PCT/IB2009/005154. Filed on: 2nd April, 2009
4. Bansal AK, Munjal B, Patel S. ***Novel self nano emulsifying curcumin (curcuminoids) composition with enhanced bioavailability.*** Indian Patent Application filed 24th July 2008, No. 1776/DEL/2008.
5. Bansal AK, Goyal M, Roy I, Banerjee U C. ***A stabilized protein composition.*** Indian Patent Application filed 23rd May 2008, No. 1268/DEL/2008.
6. Bansal AK, Puri V, Kohli G, Rao PR. ***Quick disintegrating taste masked composition.*** Indian Patent Application filed on 16th July 2007, No. 1488/DEL/2007.
7. Bansal AK, Puri V. ***Novel formulation of celecoxib.*** Indian Patent Application filed on 18th June 2007, No. 1300/DEL/2007.
8. Bansal AK, Mohammad GA, Puri V. ***An improved process for producing stavudine polymorph III.*** Indian Patent Application filed on 12th June 2007, No. 1256/DEL/2007.
9. Bansal AK, Mohammad GA, Puri V. ***A pharmaceutical composition.*** Indian Patent Application filed on 24th May 2007, No. 1118/DEL/2007.
10. Bansal AK, Kumar L, Amin A, Jain R. ***Novel acid addition salts of enalapril.*** Indian Patent Application filed 16th May 2007, No. 1064/DEL/2007.
11. Bansal AK, Kumar S, Chawla G. ***A process for producing spherical crystals of mebendazole.*** Indian Patent Application filed 3rd May 2007, No. 951/DEL/2007.
12. Bansal, AK, Bansal P, Patel S, Munjal B, Jachak S, Kohli G. ***Novel curcumin formulation.*** Provisional Indian patent, Application no. 367/DEL/2007, filed on 22nd February, 2007.

13. Bansal AK, Kakumanu V. **Method of improvement of bioavailability of prodrug, using self emulsifying drug delivery system.** Indian Patent Application filed 23rd Nov 2005, No. 3136/DEL/2005.
14. Bansal AK, Kakumanu V, Arora VK. **Gastroretentive dosage form of cephalosporin, and process of preparation thereof.** Indian Patent Application filed 23rd Nov 2005, No. 3137/DEL/2005.
15. Bansal AK, Kakumanu V. **Method of improvement of bioavailability of prodrug using solid lipid nanoparticles.** Indian Patent Application filed 23rd Nov 2005, No. 3139/DEL/2005.
16. Bansal AK, Kakumanu V, Arora VK. **Pharmaceutical composition of cefpodoxime proxetil and cyclodextrin; and process of preparation thereof.** Indian Patent Application filed 23rd Nov 2005, No. 3140DEL/2005.
17. Bansal AK, Arora S, Kaushal AM. **Improved modified release ropinirole.** Indian Patent Application filed 13th Oct 2005, No. 2755/DEL/2005.
18. Bansal AK, Banga S, Chawla G. **A process of producing improved celecoxib crystals.** Indian Patent Application filed 10th Oct 2005, No. 2709/DEL/2005.
19. Bansal AK, Trasi N, Kaushal AM, Banerjee UC, Roy N. **A stable phytase preparation.** Indian Patent Application filed 24th Dec 2004, No. 2557/DEL/2004.
20. Bansal AK, Verma S. **A process for coating highly water-soluble drugs,** Indian Patent Application filed 3rd Dec 2002, No. 1210/DEL/2002.
21. Bansal AK, Gupta P, Kakumanu V. **A process for the preparation of celecoxib composition with improved aqueous solubility.** Indian Patent Application filed 18th Nov 2002, No. 1165/DEL/2002.
22. Bansal AK, Verma S. **A taste-masking pharmaceutical composition.** Indian Patent Application filed 3rd Nov 2002, No. 1164/DEL/2002.
23. Bansal AK, Nachaegari SK. **A pharmaceutical excipient having improved compressibility for application in direct compression tableting.** Indian Patent Application filed 16th Jun 2003, No. 807/DEL/2003.
24. Bansal AK, Gupta P, Kakumanu V. **A synergistic pharmaceutical composition of celecoxib with improved aqueous solubility.** Indian Patent Application filed 26th Jun 2002, No. 685/DEL/2002.
25. Bansal AK, Gupta P, Kakumanu V. **Ternary amorphous systems for improving aqueous solubility for poorly water soluble drugs.** Indian Patent Application filed 26th Jun 2002, No. 682/DEL/2002.
26. Madan S, Bansal AK, Arora VK. **Process for the preparation of acyclovir infusion formulation.** Indian Patent Application filed 3rd Nov 2000, Granted 13th Aug 2003, No. 982/DEL/2000.
27. Gogia A, Bansal AK, Arora VK. **Process for the preparation of aqueous pharmaceutical compositions of fluoroquinolones.** Indian Patent Application filed 7th Mar 2000, No. 197/DEL/2000.

Research Papers

1. Khomane K, Meena CL, Jain R and Bansal AK. NP-647, a Novel TRH Analogue: Investigating Physicochemical Parameters Critical for its Oral and Parenteral Delivery, **International Journal of Pharmaceutics** 406 (2011) 21–30
2. Wahlang B, Pawar YB and Bansal AK. Identification of permeability-related hurdles in oral delivery of curcumin using Caco-2 cell model, **European Journal of Pharmaceutics and Biopharmaceutics** 77 (2011) 275–282
3. Kumar L, Baheti A and Bansal AK. Effect of counterion on the glass transition temperature (T_g) during lyophilization of ganciclovir salt forms, **Molecular Pharmaceutics**, Vol 8, No. 1, (2011) 309–314

4. Puri V, Dantuluri AK and Bansal AK. Investigation of Atypical Dissolution Behavior of an Encapsulated Amorphous Solid Dispersion, **Journal of Pharmaceutical Sciences**, DOI 10.1002/jps.22462
5. Patel S and Bansal AK. Prediction of Mechanical Properties of Compacted Binary Mixtures Containing High-Dose Poorly Compressible Drug, **International Journal of Pharmaceutics** 403 (2011) 109–114
6. Amin A, Chauhan S, Dare M, Bansal AK. Sorption of antimicrobial agents in blow-fill-seal packs, **Pharmaceutical Development and Technology**, DOI: 10.3109/10837450.2010.516438.
7. Patel S, Dahiya SK, Sun C and Bansal AK. Understanding Size Enlargement and Hardening of Granules on Tableability of Unlubricated Granules Prepared by Dry Granulation, **Journal of Pharmaceutical Sciences**, [Vol 100, No. 2](#), (2011) 758–766.
8. Joshi, A, Patel S and Bansal AK. Compaction studies of alternate solid forms of Celecoxib, **Advanced Powder Technology**, 21(4) (July, 2010), 452–460 (DOI:10.1016/j.apt.2010.01.006)
9. Shete, G, Puri V and Bansal AK. Solid State Characterization of Commercial Crystalline and Amorphous Atorvastatin Calcium Samples, [AAPS PharmSciTech](#). 11(2)(June 2010) 598-609
10. Puri V, Karar N, Bansal AK. Wettability and surface chemistry of crystalline and amorphous forms of a poorly water soluble drug, **European Journal of Pharmaceutical Sciences**, 2010, [Volume 40\(2\)](#), 84-93.
11. Bansal SS, Kaushal AM and Bansal AK. Enthalpy Relaxation Studies of Two Structurally Related Amorphous Drugs and their Binary Dispersions, **Drug Development and Industrial Pharmacy**, 2010, 36(11):1271-80
12. Amin A, Chauhan S, Dare M and Bansal AK. Paraben degradation by *Pseudomonas beteli* and *Bulkholderia latens*, **Eur J Pharm Biopharm**, 2010, [75\(2\)](#), 206-212.
13. Goyal MK, Roy I, Amin A, Banerjee UC, Bansal AK. Stabilization of Lysozyme by Benzyl Alcohol: Surface Tension and Thermodynamic Parameters, **Journal of Pharmaceutical Sciences**, DOI 10.1002/jps.22129
14. Patel, S. Kaushal AM and Bansal AK. Mechanistic investigation on pressure dependency of Heckel parameter. **International Journal of Pharmaceutics**, 2010, 389, 66–73
15. Rajjada D, Bansal AK, Singh S. Influence of microenvironment pH, humidity and temperature on the stability of polymorphic and amorphous forms of clopidogrel bisulphate, **AAPS Pharm Sci Tech**, 2010, DOI: 10.1208/s12249-010-9376-1
16. Srivastava A, Mishra S, Tandon P, Patel S, Ayala AP , Bansal AK and Siesler HW. Molecular structure and vibrational spectroscopic analysis of an antiplatelet drug; clopidogrel hydrogen sulphate (form 2) – A combined experimental and quantum chemical approach. **Journal of Molecular Structure**, 2010, 964, 88-96
17. Alam S, Patel S and Bansal AK. Effect of Sample Preparation Method on Quantification of Polymorphs using PXRD. **Pharmaceutical Development and Technology**, 2010
18. Bora P, Puri V and Bansal AK. Physicochemical Properties and Excipient Compatibility Studies of Probiotic *Bacillus coagulans* Spores. **Scientia Pharmaceutica**, 2009, 77(3) 625–637
19. Chawla G, Bansal AK. Molecular Mobility and Physical Stability of Amorphous Irbesartan. **Scientia Pharmaceutica**, 2009, 77(3) 695–709
20. Sharma SS, Srinivasan SK, Krishnamoorthy S, Kaushal AM and Bansal AK. Preclinical safety Pharmacology studies on the amorphous formulation of celecoxib. **Arzneimittelforschung**, 2009, 59(5), 254-262.
21. Goyal MK, Roy I, Banerjee UC, Sharma V, and Bansal AK. Role of benzyl alcohol in prevention of heat induced aggregation and inactivation of hen egg white lysozyme. **Eur J Pharm Biopharm**, 2009, 71(2), 367-376.

22. Hiwale PB, Amin A, Patel S, and Bansal AK. Variables affecting reconstitution behaviour of cefuroxime sodium for injection. **Asian Journal of Pharmaceutical Sciences**, 2009, 4(1), 23-31.
23. Kaushal A, Chakraborti AK and Bansal AK, FTIR Studies on differential intermolecular association in crystalline and amorphous states of structurally related non-steroidal anti-inflammatory drugs, **Molecular Pharmaceutics**, 2008, 5 (6), 937-945.
24. Hiwale PB, Amin A, Patel S, and Bansal AK. Reconstitution behaviour of cefuroxime sodium powder for injection. **Ind J Hosp Pharm**, 2008, 45 (July-Aug), 121-125.
25. Kumar L and Bansal AK, Preparation and Characterization of salt forms of enalapril. **Pharmaceutical Development and Technology**, 2008, 13(5), 345-357.
26. Bansal SS, Kaushal A and Bansal AK, Co-relationship of Physical stability of amorphous dispersions with enthalpy relaxation. **Die Pharmazie**, 2008, 63(11), 812-814.
27. Chawla G and Bansal AK, Improved dissolution of a poorly water soluble drug in solid dispersions with polymeric and non-polymeric hydrophilic additives. **Acta Pharmaceutica** 2008, 58 (3), 257-274.
28. Kumar S, Chawla G and Bansal AK, Spherical crystallization of mebendazole for improvement of processability. **Pharmaceutical Development and Technology**, 2008, 13(6), 559-568.
29. Mohammed GA, Puri V and Bansal AK, Co-processing of nevirapine and stavudine by spray drying. **Pharmaceutical Development and Technology**, 2008, 13(4), 299-310.
30. Kaushal A and Bansal AK, Thermodynamic behavior of glassy state of structurally related compounds. **European Journal of Pharmaceutics and Biopharmaceutics**, 2008, 69(3), 1067-1076.
31. Kakumanu VK, Arora VK, and Bansal AK. Gastro-retentive dosage form for improving bioavailability of cefpodoxime proxetil in rats. **Yakugaku Zasshi**, 2008, 128 (3), 439-445.
32. Kumar S, Chawla G and Bansal AK. Characterization of solid-state forms of mebendazole. **Die Pharmazie**, 2008;63(2):136-43.
33. Kumar S, Chawla G and Bansal AK. Role of additives like polymers and surfactants in the crystallization of mebendazole. **Yakugaku Zasshi**, 2008, 128 (2), 281-289.
34. Patel S, Kaushal AM, and Bansal AK, Compaction behavior of roller compacted ibuprofen. **Eur J Pharm Biopharm**, 2008, 69, 743-749.
35. Patel S, Kaushal AM, and Bansal AK, Lubrication potential of magnesium stearate studied on instrumented rotary tablet press. **AAPS PharmSciTech** 2007, 8(4), Article 89, E1-E8.
36. Bansal SS, Kaushal AM, and Bansal AK, Molecular and thermodynamic aspects of solubility advantage from solid dispersions. **Mol Pharm** 2007, 4(5), 794-802.
37. Chawla G, and Bansal AK, A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug. **Eur J Pharm Sci** 2007, 32, 45-57.
38. Tiwari M, Chawla G, and Bansal AK, Quantification of olanzapine polymorphs using powder X-ray diffraction technique. **J Pharm Biomed Anal** 2007, 43 (3), 865-872.
39. Patel S, Kaushal AM, Bansal AK, Effect of particle size and compression force on compaction behavior and derived mathematical parameters of compressibility. **Pharm Res** 2007, 24(1), 111-124.
40. Banga S, Chawla G, Varandani D, Mehta BR, Bansal AK, Modification of the crystal habit of celecoxib for improved processability. **J Pharm Pharmacol** 2007, 59(1), 29-39.
41. Gupta P, Bansal AK. Oral bioavailability advantage from stabilized amorphous systems of celecoxib. **Journal of Pharmaceutical Research** 2006, 5(1), 15-24.
42. Kakumanu VK, Arora VK, Bansal AK, Investigation of physicochemical and biological differences of cefpodoxime proxetil enantiomers. **Eur J Pharm Biopharm** 2006, 64, 255-259.
43. Bansal AK, Mulla M, Kakumanu VK, Criticality of functional excipients and decoding methods during generic product development. **Pharm Technol Europe** 2006, 18(6), 34-38.

44. Kakumanu VK, Arora VK, Bansal AK, Investigation of factors responsible for low oral bioavailability of cefpodoxime proxetil. *Int J Pharm* 2006, 317, 155-60.
45. Kakumanu VK, Arora VK, Bansal AK, Development and validation of isomer specific RP-HPLC method for quantification of cefpodoxime proxetil. *J Chrom B* 2006, 835, 16-20.
46. Gupta P, Bansal AK. Modeling of drug release from celecoxib-PVP-meglumine amorphous systems. *PDA Journal of Pharmaceutical Science and Technology* 2005, 59(6), 346-354.
47. Gupta P, Issa C., Bansal AK. Simultaneous determination of atenolol and furosemide in intestinal perfusion samples by validated reversed-phase high-performance liquid chromatography. *Indian Journal of Pharmaceutical Sciences* 2005, 67(6), 672-76.
48. Gupta P, Bansal AK. Ternary amorphous composites of celecoxib, poly(vinyl pyrrolidone) and meglumine with enhanced solubility. *Die Pharmazie* 2005, 60(11), 830-836.
49. Madan J, Chawla G, Arora V, Malik R, Bansal AK. Unbiased membrane permeability parameters for gabapentin using boundary layer approach. *AAPS PharmSciTech* 2005, 7(1), Article 21, E224-E230
50. Koradia VS, Chawla G, Bansal AK. Comprehensive characterization of the innovator product: Targeting bioequivalent generics. *J Generic Med* 2005, 2(4), 335-346.(Jul)
51. Rao KP, Chawla G, Kaushal AM, Bansal AK. Impact of solid-state properties on lubrication efficacy of magnesium stearate. *Pharm Dev Technol* 2005, 10(3), 423-437.
52. Gupta P, Bansal AK. Spray drying for generation of a ternary amorphous system of celecoxib, PVP, and meglumine. *Pharm Dev Technol* 2005, 10(2), 273-281.
53. Gupta P, Bansal AK. Molecular interactions in celecoxib-PVP-meglumine amorphous system. *J Pharm Pharmacol* 2005, 57(3), 303-310.(Mar)
54. Gupta P, Thilagavathi R, Chakraborti AK, Bansal AK. Role of molecular interaction in stability of Celecoxib-PVP amorphous systems. *Mol Pharm* 2005, 2(5), 384-391.
55. Gupta P, Bansal AK. Devitrification of amorphous celecoxib. *AAPS PharmSciTech* 2005, 6(2), Article 32, E223-E230.
56. Gupta P, Thilagavathi R, Chakraborti AK, Bansal AK. Differential molecular interactions between the crystalline and the amorphous phases of celecoxib. *J Pharm Pharmacol* 2005; 57(10), 1271-1278.
57. Gupta P, Kakumanu VK, Bansal AK. Stability and solubility of celecoxib-PVP amorphous dispersions: a molecular perspective. *Pharm Res* 2004, 21(10), 1762-1769.
58. Gupta P, Chawla G, Bansal AK. Physical stability and solubility advantage from amorphous celecoxib: The role of thermodynamic quantities and molecular mobility. *Mol Pharm* 2004, 1(6), 406-413.
59. Koradia V, Chawla G, Bansal AK. Qualitative and quantitative analysis of clopidogrel bisulfate polymorphs. *Acta Pharmaceutica* 2004, 54(3), 193-204.
60. Chawla G, Bansal AK. Effect of processing on celecoxib and its solvates. *Pharm Dev Technol* 2004, 9(4), 419-433.
61. Puri V, Bansal AK. In vitro - in vivo characterization of release modifying agents for parenteral sustained-release ketorolac formulation. *Drug Dev Ind Pharm* 2004, 30(6), 619-626.
62. Issa C, Gupta P, Bansal AK. Intestinal permeation mediated absorption interactions between atenolol and furosemide. *Indian J Pharm Sci* 2003, 65(6), 631-633.(Nov-Dec)
63. Chawla G, Gupta P, Thilagavathi R, Chakraborti AK, Bansal AK. Characterization of solid-state forms of celecoxib. *Eur J Pharm Sci* 2003, 20(3), 305-317.
64. Issa C, Gupta P, Bansal AK. Implications of density correction in gravimetric method for water flux determination using rat single-pass intestinal perfusion technique: A technical note. *AAPS PharmSciTech* 2003, 4(2), Article 16, 133-138.

65. Vasukumar, K, Bansal AK. Enthalpy relaxation studies on celecoxib amorphous mixtures. **Pharm Res** 2002, 19(12), 1873-1878.
66. Bansal AK, Khar RK, Dubey R, Sharma AK. Benzyl ester prodrug of ibuprofen: pharmacological and toxicological profile. **Bolletino Chimico Farmaceutico** 2001, 140(2), 79-82.(Mar/Apr)
67. Bansal AK, Khar RK, Dubey R, Sharma AK. Alkyl ester prodrugs for improved topical delivery of ibuprofen. **Indian J Exp Biol** 2001, 39(3), 280-283.(Mar)
68. Bansal AK, Khar RK, Dubey R, Sharma AK. Activity profile of glycolamide ester prodrugs of ibuprofen. **Drug Dev Ind Pharm** 2001, 27(1), 63-70.
69. Bansal AK, Dubey R, Khar RK. Quantitation of activity of alkyl ester prodrugs of ibuprofen. **Drug Dev Ind Pharm** 1994, 20(12), 2025-2034.
70. Bansal AK, Khar RK, Dubey R, Sharma AK. Effect of group substitution on the physicochemical properties of ibuprofen prodrugs. **Die Pharmazie** 1994, 49(6), 422-424.
71. Kakkar AP, Gulati RK, Bansal AK. Solvent deposition of chlordiazepoxide on starch lactose granules. **Indian J Pharm Sci** 1993, 55(6), 212-217.
72. Bansal AK, Kakkar AP. Solvent deposition system of salbutamol and sucrose pellets. **Indian Drugs** 1991, 28(10), 481-482.
73. Bansal AK, Kakkar AP. Solvent deposition of diazepam over sucrose pellets. **Indian J Pharm Sci** 1990, 52, 186-187.

Review Articles

1. Hiwale P, Amin A, Kumar L and Bansal AK, Variables affecting reconstitution time of dry powder for injection. **Pharm Tech**, 2008, 32(7), 62-68.
2. Kumar L, Amin A and Bansal AK, Salt selection in drug development. **Pharm Tech**, 2008, 32(3), 128-146.
3. Kumar L, Amin A, Bansal AK, An overview of automated approaches relevant in pharmaceutical salt screening. **Drug Discov Today** 2007, 12(23-24), 1046-1053.
4. Bansal SS, Joshi A, Bansal AK, New dosage formulations for targeted delivery of cyclo-oxygenase-2 inhibitors: Focus on use in the elderly. **Drugs and Aging** 2007, 24(6), 441-451.
5. Amin A, Bansal AK, Formulation development for sterile liquid products in blow-fill-seal packs. **Pharm Technol** 2006, 30(10), 142-154.
6. Patel S, Kaushal AM, Bansal AK, Compression physics in the formulation development of tablets. **Crit Rev Ther Drug Carr Sys** 2006, 23(1), 1-65.
7. Shah B, Kakumanu V, Bansal AK, Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. **J Pharm Sci** 2006, 95(8), 1641-1665.
8. Bansal AK, Koradia V. The role of reverse engineering in the development of generic formulations. **Pharm. Technol** 2005, 29(8), 50-55. (Aug)
9. Kaushal AM, Gupta P, Bansal AK. Amorphous drug delivery systems: Molecular aspects, design, and performance. **Crit Rev Ther Drug Carr Sys** 2004, 21(3), 133-193.
10. Nachaegari, SK, Bansal AK. Coprocessed excipients for solid dosage forms. **Pharm Technol** 2004, 28(1), 52-64. (Jan)
11. Bansal AK. Improved excipients by solid-state manipulation. **The Industrial Pharmacist**, 2003, Issue 31, 9-12. (Dec)
12. Chawla G, Gupta P, Koradia V, Bansal AK. Gastroretention – A means to address regional variability in intestinal drug absorption. **Pharm Technol** 2003, 27(7), 50-68. (Jul)
13. Gupta P, Bansal AK. Patent opportunities in matrix based oral controlled release drug delivery systems, Part II. **Pharm Technol Europe** 2002, 14(10), 47-54. (Oct)

14. Gupta P, Bansal AK. Patent opportunities in matrix based oral controlled release drug delivery systems, Part I. *Pharm Technol Europe*, 2002, 14(9), 49-59. (Sept)
15. Gupta P, Bansal AK. Patent opportunities in matrix based oral controlled release drug delivery systems, Part I. *Pharm Technol Asia*, Aug 2002, 13-20. (Special Issue)
16. Bansal AK. Product development issues of powders for injection. *Pharm Technol* 2002, 26(3), 122-132. (Mar)

General Articles

1. Kumar S, Kaushal AM, Bansal AK, Regulating follow-on bio-products, *Chronicle Pharmabiz* 2006, Nov. 30, 43-46.
2. Chawla G, Bansal AK. Making improved generic products. *Pharmabiz* 2006, February issue.
3. Arora S, Kaushal AM, Bansal AK. Role of powder characteristics in the design of dry powder inhalers. *CRIPS* 2005, 6(1), 7-11. (Jan-Mar)
4. Bansal AK. Developing industry responsive courses in academic institutions. *Express Pharma Pulse* Special Feature: 56th Indian Pharmaceutical Congress, Dec 2004, 24-25.
5. Banga S, Chawla G, Bansal AK. New trends in crystallization of active pharmaceutical ingredients. Business Briefing: *Pharmagenerics 2004*, 70-74.(Nov)
6. Kakumanu V, Bansal AK. Supercritical fluid technology in pharmaceutical research. Business briefings: *Labtech 2004*, 70-72.(Sept)
7. Chawla G, Banga S, Bansal AK. High throughput polymorph screening of pharmaceuticals – ‘Farming for crystal mutants’. *Business Briefing: Future Drug Discovery 2004*, 66-72.(Mar)
8. Chawla G, Bansal AK. Challenges in polymorphism of pharmaceuticals. *CRIPS* 2004, 5(1), 12-15. (Jan-Mar)
9. Chawla G, Bansal AK. Regulatory issues related to polymorphism. *Express Pharma Pulse 2003*, 9 (49), 8.(Oct 30)
10. Chawla G, Bansal AK. Polymorphism: Challenges and opportunities. *Express Pharma Pulse* 2003, 9 (48), 10.(Oct 23)
11. Bansal AK, Gupta P. Peroral controlled DDS : Future trends. *Express Pharma Pulse* Special feature: Pharma Technology, May 2003, 39-42.
12. Kakumanu V, Bansal AK. Supercritical fluid technology in pharmaceutical research. *CRIPS* 2003, 4(2), 8-12.(Apr-Jun)
13. Bansal AK, Nachaegari SK. High functionality excipients in solid dosage forms. *Business Briefings: PharmaGenerics 2002*, 38-44.(Sept)
14. Puri V, Bansal AK. Pharmaceutical technology: Challenges and opportunities. *CRIPS* 2001, 2(4), 2-11.
15. Verma S, Bansal AK. SUPAC: A scientific approach for scale-up. *Express Pharma Pulse*, Oct 2001, 11.
16. Verma S, Bansal AK. SUPAC: Reduce testing and reporting needs. *Express Pharma Pulse*, Oct 2001, 11.
17. Verma S, Bansal AK. Genesis of SUPAC-IR guidance. *Express Pharma Pulse*, Sept 2001, 20.
18. Singh S, Garg S, Bansal AK. The quality of pharmaceutical products exported from India and the soundness of dossiers submitted by Indian exporters. *Pharma Times*, May 2001, 33, 12-16.

Book Chapters

1. Sonje VM, Kumar L, Meena CL, Kohli G, Puri V, Jain R, Bansal AK and Brittain HG. **Atorvastatin calcium**. In: Brittain HG, editor. **Profiles of drug substances, excipients, and related methodology**. San Diego, CA, USA: Academic Press 2010, 1-70.
2. Kumar L, Alam MS, Meena CL, Jain R and Bansal AK. **Fexofenadine hydrochloride**. In: Brittain HG, editor. **Profiles of drug substances, excipients, and related methodology**. San Diego, CA, USA: Academic Press 2009, 153-192.
3. Gupta P, Nachaegari SK, Bansal AK. **Improved excipient functionality by coprocessing**, In: Katdare A, Chaubal MV, editors. **Excipient development for Pharmaceutical, Biotechnology, and Drug delivery Systems**. New York: Informa Healthcare 2006, 109-26.
4. Chawla G, Gupta P, Bansal AK. **Gastroretentive drug delivery systems**. In: Jain NK, editor. **Progress in controlled and novel drug delivery systems**. New Delhi: CBS Publishers and Distributors 2004, 76–97.
5. Bansal AK. **Overview of modern parenteral products and processes**. In: Williams K, editor. **Microbial contamination control in parenteral manufacturing**. New York: Marcel Dekker 2004, 59–90.

Interaction with the pharmaceutical industry

Globalization of Indian pharmaceutical industry has introduced new scientific, regulatory and intellectual property challenges in the area of drug discovery and development. The industry expects academic institution to respond to their emerging needs in research and development. Realizing this, our laboratory has established strong ties with the Indian pharmaceutical industry. Our research activities are broadly divided into pre-formulation profiling and formulation development. Pre-formulation activities include solubility, permeability, stability, compaction physics and compatibility studies. Our laboratory has developed expertise in material characterization including salt form selection, polymorph studies, surface characterization and crystal engineering. Based on the pre-formulation profile suitable interventions for improvement of aqueous solubility and permeability are applied.

Indian pharmaceutical companies have made their strong presence globally in the generic market. We have significantly contributed to the development of generic formulations by proposing a decision tree for reverse engineering of the innovator products. We have expanded the concept of 'sameness' of the generic formulations to the concept of 'sameness of formulation'. This leads to accelerated development of generic formulations and also improves probability of development of a generic formulation. [Bansal AK, Koradia V. The role of reverse engineering in the development of generic formulations. **Pharm Technol** 2005, 29(8), 50-55. (Aug)]. To this effect we have performed characterization of over 50 innovator formulations, for numerous leading generic exporters to advanced markets like USA and Europe.

Our laboratory has collaborated with numerous Indian and overseas pharmaceutical companies in the area of

- **Solid state material characterization**
- **Quantification of polymorphic forms**
- **Formulation development of conventional / modified release formulations**
- **Process optimization**
- **Development of value added generics**
- **Development of lyophilization cycle**
- **Technical support for patent litigation**

We have collaborated with numerous overseas and Indian pharmaceutical companies (a selected list is given below) on sponsored projects.

Medochemie Limited, Cyprus; Reckitt Benckiser, USA; JM Pharma, LLC, USA; DSM Anti-Infectives, Netherlands; United Laboratories, Philippines; Montajat Veterinary Pharmaceutical, Saudi Arabia; Sandoz Private Limited; Ranbaxy Research Labs; Dr. Reddy's Laboratories; Nicholas Piramal; Zydus Cadila Limited; Dabur India Limited; Panacea Biotech; Strides Arcolab; Jubilant Organosys; Natco Pharma; Alpha Drugs, Famy Care Limited; Alkem Labs; Promed Exports Private Limited; UCB Limited; Lupin Labs; Aurobindo Pharma; Macleods; Orchid Pharma; Ind-Swift Labs; Torrent Pharmaceuticals; Lupin Limited; Getz Pharma Research.